NCT03430830View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

April 9, 2018

Study Completion Date

April 9, 2018

Conditions
Chronic Hepatitis c
Interventions
DRUG

Ravidasvir 50mg

50mg, Tablet

DRUG

Ravidasvir 200mg

200mg, Tablet

Trial Locations (1)

310003

First Hospital of Zhejiang Province, Hangzhou

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY